Radevych, І.Siromolot, AndriyKolybo, Denys2025-03-112025-03-112024Radevych, І. І. Synergistic anti-tumour effect of doxorubicin-hydrochloride with CRM197, an inhibitor of HB-EGF, in squamous-cell carcinoma / I. I. Radevych, A. A. Siromolot, D. V. Kolybo // Biotechnologia Acta. - 2024. - Vol. 17, No 2. - Р. 64-66. - https://doi.org/10.15407/biotech17.02.0642410-77512410-776Xhttps://doi.org/10.15407/biotech17.02.064https://ekmair.ukma.edu.ua/handle/123456789/33877Сancer is one of the greatest threats to public health, its lethality comparable only to that of cardiovascular diseases, with the approach to its prevention and therapy evolving from populationbased and epidemiological studies to targeted delivery and immunological approaches. Recent studies have shown that cross reacting material (CRM197), a nontoxic variant of diphtheria toxin may play an important role in treating cancers with poor prognoses by inhibiting heparin-binding EGF-like growth factor (HB-EGF) [1, 2]. Doxorubicin-hydrochloride (DOX) is an antineoplastic prescription medicine approved by the U.S. Food and Drug Administration for the treatment of certain types of cancer, including ovarian cancer and multiple myeloma [3]. Considering that CRM197 is a known carrier in targeted delivery, CRM197-DOX complexes might be a step towards targeted therapy and reduced overall toxicity.enCRM197doxorubicinepidermoid carcinomatargeted treatmentconference materialsConference materials